FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of October 2004
AETERNA ZENTARIS INC.
------------------------------------------
(Formerly named AEterna Laboratories Inc.)
1405, boul. du Parc-Technologique
Quebec, Quebec
Canada, G1P 4P5
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.
Form 20-F Form 40-F X
------ ------
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934
Yes No X
----- -----
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
-----
DOCUMENTS INDEX
DOCUMENTS DESCRIPTION
--------- -------------------------------------------------------------------
1. Press release dated October 28, 2004 - AEterna Zentaris Announces Third
Quarter Financial Results Conference Call and Webcast
[AETERNA ZENTARIS LOGO]
AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881
www.aeternazentaris.com
PRESS RELEASE
For immediate release
AETERNA ZENTARIS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS
CONFERENCE CALL AND WEBCAST
QUEBEC CITY, CANADA, OCTOBER 28, 2004 - AEterna Zentaris Inc. (TSX: AEZ;
Nasdaq: AEZS) announced that its quarterly conference call and webcast have
been scheduled for Thursday, November 4, 2004 at 10:00 a.m. Eastern time. The
call will follow the press release of AEterna Zentaris' third quarter 2004
financial results issued earlier on the same day. Participants may access the
live webcast via the Company's website at www.aeternazentaris.com in the
"investors" section, or by telephone using the following numbers: 416-640-4127,
514-807-8791 or 1-800-814-4941.
A replay of the webcast will also be available on the website for a period of 30
days.
AEterna Zentaris is a biopharmaceutical company with an extensive portfolio of
marketed and development-stage products in oncology, endocrine therapy and
infectious diseases.
-30-
CONTACTS:
MEDIA RELATIONS INVESTOR RELATIONS
Paul Burroughs Jacques Raymond
(418) 652-8525 ext. 406 (418) 652-8525 ext. 360
paul.burroughs@aeternazentaris.com jacques.raymond@aeternazentaris.com
U.S. INVESTOR RELATIONS EUROPE
Lippert/Heilshorn & Associates Matthias Seeber
Kim Golodetz +49 69 42602 3425
(212) 838-3777 matthias.seeber@zentaris.de
kgolodetz@lhai.com
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
AETERNA ZENTARIS INC.
Date: October 28, 2004 By: /s/ Mario Paradis
----------------------- ---------------------------
Mario Paradis
Senior Finance Director and
Corporate Secretary